Samsung Biologics

Beta

KRX Filings & Disclosures 2026

Risk Factors

• • FX risk primary exposure: sales, purchases, and borrowings denominated in USD (functional currency KRW); forward contracts available as hedge tool but not currently in use
• • Credit risk maximum exposure equals carrying value of financial assets; client creditworthiness assessed via financial statements and pipeline development stage

Management Discussion & Analysis

• • Samsung Biologics FY2025 revenue KRW 4,557B, up 30.31% YoY; operating profit KRW 2,069B, up 56.60% YoY; net income KRW 1,784B, up 64.71% YoY
• • Growth driven by Plants 1–3 full utilization, Plant 4 ramp-up, and favorable FX impact on CDMO revenue

Business Overview

• • Pure-play CDMO focus achieved via Nov 2025 spin-off of Samsung Epis Holdings (삼성에피스홀딩스), separating biosimilar business to eliminate conflict-of-interest concerns
• • FY2025 consolidated revenue KRW 4.557T (+30% YoY), operating profit KRW 2.069T (+57% YoY); total production capacity 785,000L across 5 plants in Songdo

What are the latest Samsung Biologics DART filings in 2026?

Samsung Biologics (KRX code 207940) has filed an annual report on March 12, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did Samsung Biologics file its most recent annual report?

Samsung Biologics filed its most recent annual report on March 12, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is Samsung Biologics's KRX stock code?

Samsung Biologics's KRX stock code is 207940. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 207940 to look up all Samsung Biologics disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does Samsung Biologics file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for Samsung Biologics.

Where can I find Samsung Biologics financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from Samsung Biologics annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.